InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Cvergenx Inc. to Collaborate in Novel Approach to Personalized Radiotherapy and Drug Discovery
February 23, 2023
Predictive Oncology (NASDAQ: POAI) and Cvergenx today announced an agreement to form a strategic partnership that will potentially revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery. According to the announcement, the collaboration’s objective is to leverage and maximize the combined power of proprietary technologies […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names New Chief Business Officer
February 22, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery, has announced the appointment of a new chief business officer. The company has named veteran Pamela Bush to the role. Bush was featured during a recent Proactive video release, during which she and host Natalie Stoberman discussed her new assignment. […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Program to Partner Academic, Research Institutions to Assist with Drug-Discovery Initiatives
February 21, 2023
Predictive Oncology (NASDAQ: POAI) launched a program designed to advance the oncology drug-development initiatives with academic and research institutions. The program, called ACE, partners with early-stage academic and research institutions to assist in advancing their efforts and focus on drug discovery. The program provides access to POAI’s PEDAL platform, which brings together active machine learning with […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Seasoned Veteran as New Chief Business Officer
February 3, 2023
Predictive Oncology (NASDAQ: POAI) has announced a new chief business officer. Effective immediately, Pamela Bush, PhD, MBA, will take on the role as chief business officer and will oversee all business development including the partnering and growth strategies for the company. Specifically, the company observed that she will manage the company’s strategic, operational and financial […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Computational Biology Pioneer as New Scientific Advisory Board Member
January 12, 2023
Predictive Oncology (NASDAQ: POAI) has announced a new member of its Scientific Advisory Board: Robert F. Murphy, PhD, a pioneer in the field of machine learning and analytics for biological data, will be joining the board and working with other experts in a variety of fields to guide the POAI’s scientific initiatives and growth strategy. […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Expands Scientific Advisory Board to Appoint Genomics Expert
December 13, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of Marc Malandro, Ph.D., to the company’s scientific advisory board. Dr. Malandro, a highly regarded scientific leader and expert in genomics, molecular biology, biochemistry and bioengineering, will serve alongside other key thought […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Member
December 5, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed a new board member; Matthew J. Hawryluk, PhD, will “help support the company’s strategic initiatives and commercialization efforts.” A well-known business executive in the pharma and biotech industries, Hawryluk currently serves as executive vice […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q3 Financial Report, Corporate Update
November 11, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting corporate updates and financial results for its Q3 quarter, ended Sept. 30, 2022. According to the announcement, the report reflects revenue growth and increased gross profit margin as compared to prior year periods. Highlights […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Key Life Sciences Thought Leader to Its Board
October 25, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its appointment of David S. Smith, JD, to the company’s board of directors. Smith is a life sciences and corporate attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Names Seasoned Senior Exec, Biotech Entrepreneur as New CEO
October 20, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Raymond F. Vennare as its new chief executive officer, effective Nov. 1, 2022; Vennare will also assume the role of board chair. Vennare has more than 30 years’ experience building and leading biotechnology and […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2023 Financial, Corporate Report
August 12, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting its financial results for Q1 2023, or the period ended June 30, 2022. In addition, the company also released a corporate update for the company, […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 Financial Report
August 12, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting its numbers for second quarter 2022, or the period ended June 30, 2022. According to the announcement, the report indicates a strong balance sheet with a solid cash balance, commensurate equity and no debt. […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Names Chief Scientific Officer, Shares R&D Update
July 26, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Julia Kirshner, PhD, as its new chief scientific officer. Kirshner has been serving as POAI’s senior vice president as well as president of the company’s zPREDICTA division, a company that she originally founded in […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes on $7.2M in Registered Direct Offerings
May 19, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on two direct offerings. The offerings, which were available concurrently, were with different institutional investors and results in approximately $7.2 million in gross proceeds for the company, before the deduction of […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $7.2M Registered Direct Offerings
May 16, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional investors for the issuance and sale of shares of its common stock, with related agreements regarding certain stock purchase warrants, in connection with two concurrent offerings. […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases Q1 Financial Report, Corporate Update
May 13, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released financial results from its first quarter, the period ending March 31, 2022. Highlights from the report include recognized revenue of $314,568 for the quarter, up from $280,317 reported for the same period in 2021; […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Experienced Leader as Senior Director of Marketing
April 26, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop optimal cancer therapies, today announced that Theresa Ferguson has been named senior director of marketing. As the company’s senior marketing leader, Ferguson steps in as Predictive Oncology begins commercialization of its knowledge-driven technologies, applying artificial intelligence (“AI”) to develop personalized […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases Year-End 2021 Financial Report, Corporate Update
April 1, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting its financial and corporate results for the year ended Dec. 31, 2021. Highlights of the report include positive results of POAI subsidiary Helomics’ Discovery 21 proof of concept of its PeDAL(R) platform, added revenue […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Calls Validation of Discovery 21 Proof-of-Concept Campaign a ‘Key Milestone’
March 24, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had reached a key milestone toward monetizing its unique approach to leverage AI in oncology drug discovery. The company noted that earlier this year its proprietary Discovery 21 proof-of-concept campaign showed the ability […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Plans to Market Proprietary AI Drug-Discovery Platform
January 27, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is focused on establishing a position as a first mover in the artificial intelligence (“AI”)-powered, drug-discovery market. According to the announcement, the company anticipates the space will reach $20 billion in the next three years. As […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Strong Results from Discovery 2021 Program
January 13, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today reported the preliminary results of its Discovery 2021 program. According to the update, Predictive Oncology’s Helomics subsidiary’s evaluation demonstrated its proprietary artificial intelligence (“AI”) program CoRE(TM) (Computational Research Engine), combined with its tumor profile data and […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Reschedules Adjournment of Annual Stockholder Meeting
December 28, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced a new time for its annual meeting of stockholders. The meeting was originally scheduled for Dec. 23, 2021, at 3 p.m. CT, but upon convening was immediately adjourned because a required quorum was not in […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Year-End Shareholder Update
December 21, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today issued a year-end corporate update. Among the highlights, the update discussed POAI’s November 2021 acquisition of zPREDICTA, a cutting-edge cancer based company with a proven commercial and scientific record and patented 3D cell culture platform. “zPREDICTA’s […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Welcomes New SVP of Strategic Sales and Business Development
December 7, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today announced that Pamela Bush, Ph.D., MBA will be joining the company’s leadership team as SVP of Strategic Sales and Business Development. According to the update, Bush brings to POAI’s leadership team nearly two decades of experience […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces zPREDICTA Acquisition
December 1, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, has completed the acquisition of zPREDICTA. According to the announcement, the acquisition provides an immediate new anticipated revenue stream for POAI as well as supporting the company focus on developing new cancer therapies from drug discovery through […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Website Showcasing AI-Driven Advancements in Cancer Research
October 19, 2021
Predictive Oncology (NASDAQ: POAI), an oncology and cancer research company using big data and machine learning to improve pharmaceutical development and predictive treatment outcomes, today announced the launch of a website that emphasizes its role in advancing its mission. According to the update, the website features information about Predictive Oncology and its subsidiaries, which are […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Approval of Charter Amendment
August 18, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that on Aug. 17, 2021, the stockholders approved an amendment to the company’s certificate of incorporation. The amendment, effective Aug. 17, 2021, increased the number of authorized shares of company common stock from 100,000,000 […]
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary AI Model Predicts Cancer Outcomes, Leads to New Therapies
August 17, 2021
AI models of genomic data can predict cancer outcomes, which can then help personalize ovarian cancer treatments Results come from Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research Library Model learns patterns in genetic mutations of patients’ tumors, uses that knowledge to predict patient survival In an historic announcement in […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Adjournment of Special Meeting of Stockholders
August 11, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at 3 p.m. CT, and then adjourned, with a plan to reconvene on Aug. 17, 2021, at 3 p.m. CT. The […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs
July 27, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Stands Distinct in Precision Medicine
July 16, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development […]
InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiaries Showcase Products, Services at BIO Digital
July 9, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech partnering event held virtually on June 10-11 and 14-18, 2021, through its three subsidiaries. “While informative, the thrust of attending […]
Predictive Oncology Inc. (NASDAQ: POAI) Companies Build New Labs, Expand Services for New Drug Discoveries
July 7, 2021
Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customers With its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to clinical trials, as well as manufacture proprietary media used in its chromatography kits TumorGenesis will use its GMP lab to […]
Predictive Oncology Inc. (NASDAQ: POAI) Stands Strong as Innovator, Leader in Precision Medicine
July 2, 2021
Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilities POAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in the space Predictive Oncology is strong standout in precision medicine Predictive Oncology (NASDAQ: POAI) has closed on its registered direct […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases
July 2, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology […]
Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference
June 24, 2021
More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021 Companies leveraged different components of the conference to entertain new partnerships or customers Every industry has a revolving calendar of events, but some are […]
Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer
June 22, 2021
Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes. Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process. Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building Strong Commercial Pipeline for Unique PeDAL(TM) Platform
June 2, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We […]
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Highlights, Q1 Financials Herald Bright Horizon for Company
May 28, 2021
POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises Company subsidiaries reached several milestone achievements throughout the quarter. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Adds Insight, Strengthens Positioning Through Strategic Board Appointment
May 26, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently expanded its board of directors with the appointment of Dr. Christina Jenkins. Dr. Jenkins holds capital markets expertise coupled with health care experience through roles that span clinical medicine, venture capital, health plans, and health […]